Neutropenia after rituximab treatment: New insights on a late complication

Current Opinion in Hematology

Volumn 19, Issue 1, 2012, Pages 32-38

  Wolach, Ofir ^a,b   Shpilberg, Ofer ^a,b   Lahav, Meir ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Late onset neutropenia; Neutropenia; Rituximab

Indexed keywords

CD20 ANTIBODY; FC RECEPTOR; MONOCLONAL ANTIBODY; RITUXIMAB; IMMUNOLOGIC FACTOR;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; B LYMPHOCYTE; CELLULAR IMMUNITY; DISEASE SEVERITY; HISTORY; HUMAN; HUMORAL IMMUNITY; MORBIDITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REVIEW; RISK; RISK FACTOR; CHEMICALLY INDUCED DISORDER; INCIDENCE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; NEUTROPENIA; RISK FACTORS;

EID: 84856403087     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32834da987     Document Type: Review

References (56)

1. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007; 26:3603-3613.
2. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-473.
3. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010; 237:264-283.
4. Berentsen S. Rituximab for the treatment of autoimmune cytopenias. Haematologica 2007; 92:1589-1596.
5. Carr DR, Heffernan MP. Off-label uses of rituximab in dermatology. Dermatol Ther 2007; 20:277-287.
6. Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006; 5:18-24.
7. Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy - rare but there! Leuk Lymphoma 2009; 50:1083-1095.
8. Benyunes M, Multani P, Saunders A. Neutropenia in patients treated with rituximab [response letter]. N Engl J Med 2003; 348:2691-2694.
9. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010; 89:308-318.
10. Chaiwatanatorn K, Lee N, Grigg A, et al. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 2003; 121:913-918.
11. Fukuno K, Tsurumi H, Ando N, et al. Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma. Int J Hematol 2006; 84:242-247.
12. Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33:921-923.
13. Nitta E, Izutsu K, Sato T, et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 2007; 18:364-369.
14. Stamatopoulos K, Papadaki T, Pontikoglou C, et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximabtreated lymphoma patients with late-onset neutropenia. Leukemia 2008; 22:1446-1449.
15. Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections. Arthritis Rheum 2011; 63:2209-2214.
16. Tesfa D, Gelius T, Sander B, et al. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol 2008; 25:374-379.
17. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment. J Clin Oncol 2000; 18:3135-3143.
18. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
19. Li SC, Chen YC, Evens AM, et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcgammaRIIIa 158(V/F) polymorphism. Am J Hematol 2010; 85:810-812.
20. Tobinai K, Igarashi T, Itoh K, et al. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study. Cancer Sci 2011; 102:1698-1705.
21. Dunleavy K, Hakim F, Kim HK, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005; 106:795-802.
22. Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006; 47:1013-1017.
23. Hirayama Y, Kohda K, Konuma Y, et al. Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab. Intern Med 2009; 48:57-60.
24. Lai GG, Lim ST, Tao M, et al. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol 2009; 84:414-417.
25. Rios-Fernandez R, Gutierrez-Salmeron MT, Callejas-Rubio JL, et al. Lateonset neutropenia following rituximab treatment in patients with autoimmune diseases. Br J Dermatol 2007; 157:1271-1273.
26. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60:2156-2168.
27. Cairoli R, Grillo G, Tedeschi A, et al. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica 2004; 89:361-363.
28. Flinn IW, O'Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6:628-632.
29. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103:777-783.
30. Kato H, Yamamoto K, Matsuo K, et al. Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stemcell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events. Ann Oncol 2010; 21:1699-1705.
31. Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010; 28:279-284.
32. Keane C, Nourse JP, Crooks P, et al. Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B cell lymphoma. Intern Med 2011 [Epub ahead of print].
33. McIver Z, Stephens N, Grim A, Barrett AJ. Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged lifethreatening cytopenias. Biol Blood Marrow Transplant 2010; 16:1549-1556.
34. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003; 348:2691-2694; discussion 2691-2694.
35. Christopeit M, Haak U, Behre G. Late-onset neutropenia following viral bone marrow depression after rituximab therapy. Ann Hematol 2008; 87:761-762.
36. Klepfish A, Rachmilevitch E, Schattner A. Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment. Eur J Intern Med 2006; 17:505-507.
37. Papadaki T, Stamatopoulos K, Stavroyianni N, et al. Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: report of two cases. Leuk Res 2002; 26:597-600.
38. Liu JH, Wei S, Lamy T, et al. Chronic neutropenia mediated by fas ligand. Blood 2000; 95:3219-3222.
39. Coakley G, Iqbal M, Brooks D, et al. CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty's and large granular lymphocyte syndromes. Arthritis Rheum 2000; 43:834-843.
40. Papadaki T, Stamatopoulos K, Anagnostopoulos A, Fassas A. Rituximabassociated immune myelopathy. Blood 2003; 102:1557-1558.
41. Grant C, Wilson WH, Dunleavy K. Neutropenia associated with rituximab therapy. Curr Opin Hematol 2011; 18:49-54.
42. Terrier B, Ittah M, Tourneur L, et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFFinduced B-cell recovery. Haematologica 2007; 92:e20-e23.
43. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635-2642.
44. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti- CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-758.
45. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-3947.
46. Murawski N, Pfreundschuh M. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol 2010; 11:1074-1085.
47. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 2010; 28:3525-3530.
48. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-4402.
49. Beers SA, Chan CH, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008; 112:4170-4177.
50. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002; 62 (Suppl 1):1-15.
51. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 2011; 15:e2-e16.
52. Shortt J, Spencer A. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 2006; 38:433-436.
53. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007; 146:657-665.
54. Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer 2010; 10:425-434.
55. Andres E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 2008; 15:15-21.
56. Hincks I, Woodcock BE, Thachil J. Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferatve disorders? Br J Haematol 2011; 153:411-413.